ArticleCell cycle (Georgetown, Tex.)2020
Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients.
Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- HOXA2 exerts anti-renal fibrosis effects through reducing endoplasmic reticulum stress via the upregulation of SIRT1.Communications biology · 2025Article
- HOX gene dysregulation in glioblastoma: a narrative review of current advances.Discover oncology · 2025Review
- Epigenetic regulation of HOXA2 expression affects tumor progression and predicts breast cancer patient survival.Cell death and differentiation · 2025Article
- Effect of MPP2 and its DNA methylation levels on prognosis of colorectal cancer patients.World journal of surgical oncology · 2024Article
- Role of HOXA1-4 in the development of genetic and malignant diseases.Biomarker research · 2024Review
- Article
- The impact ofAnimal cells and systems · 2024Article
- Expression and clinical significance of RBBP4 gene in lower-grade glioma: An integrative analysis.Biochemistry and biophysics reports · 2023Article
- Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family.Discover oncology · 2023Article
- KCNJ14 knockdown significantly inhibited the proliferation and migration of colorectal cells.BMC medical genomics · 2022Article
- Identification of a pyroptosis-related prognosis gene signature and its relationship with an immune microenvironment in gliomas.Medicine · 2022Article
- The Role of E3 Ligase Pirh2 in Disease.Cells · 2022Review
- GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma.Frontiers in oncology · 2022Article
- Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.Molecular medicine (Cambridge, Mass.) · 2021Article
- Role of RHOC in evaluating an adverse prognosis in patients with glioma and its potential prognostic value.Molecular and clinical oncology · 2021Article
- GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.Cancer cell international · 2021Article
- ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma.Frontiers in genetics · 2021Article
- Article
- Pan-Cancer Genome-Wide DNA Methylation Analyses Revealed That Hypermethylation Influences 3D Architecture and Gene Expression Dysregulation in HOXA Locus During Carcinogenesis of Cancers.Frontiers in cell and developmental biology · 2021Article
- Identification of Prognostic Biomarkers Among FAM83 Family Genes in Human Ovarian Cancer Through Bioinformatic Analysis and Experimental Verification.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, studies have revealed HOXA2 as a new oncogene, but its function is unknown in gliomas. We aimed to reveal the relationship between HOXA2 and glioma based on the Chinese Glioma Genome Atlas(CGGA) and the cancer genome atlas (TCGA). HOXA2 expression data and clinically relevant information of glioma patients were obtained from the CGGA and TCGA containing 1447 glioma tissues and five non-tumor brain tissues. The Wilcox or Kruskal tests were used to detect the correlation between the HOXA2 expression level and clinical data of glioma patients. the Kaplan-Meier method were used to examine the relationship between HOXA2 and overall patient survival. Gene set enrichment analysis (GSEA) was conducted to indirectly reveal the signaling pathways involved in HOXA2, and RT-PCR was used to detect HOXA2 expression in gliomas and non-tumor brain tissues. High HOXA2 expression was found to be positively correlated with clinical grade, histological type, age, and tumor recurrence, but negatively correlated with 1p19 codeletion and isocitrate dehydrogenase mutation status.RT-PCR results showed that HOXA2 expression levels were significantly higher in tumor tissues than in non-tumor brain tissues. GSEA showed that HOXA2 promoted the activation of the activation of the JAK-STAT-signaling pathway, focal adhesion, cell-adhesion-molecules-CAMS pathway, cytosolic DNA sensing pathway, and natural killer cell-mediated cytotoxicity. This study revealed for the first time that the novel oncogene,HOXA2, leads to poor prognosis in gliomas, and can be used as a biomarker for the diagnosis and treatment of gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.